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ABSTRACT 
Objective: Induction chemotherapy (IC) and concurrent chemoradiotherapy (CCRT) for locally advanced head and 
neck cancer has been studied in many clinical trials. This study was conducted to determine the response rate of IC with 
paclitaxel, ifosfamide, and cisplatin followed by CCRT with cisplatin for this group of patients, and the effect of the 
entire treatment on survival and time to disease progression.  
Methods: Thirty patients with advanced and unresectable head and neck cancer were treated with 2 cycles of 
induction paclitaxel/ ifosfamide/ cisplatin. If the primary tumor had a complete or partial response, patients were treated 
with 2 more cycles of IC followed by radiotherapy 70 Gy plus 3 cycles of cisplatin. For those with less than partial 
response or disease progression were treated according to the discretion of the physicians. 
Results: Ninety percent of patients had stage IV disease and 40% of them had primary tumor at maxillary sinus and 
nasal cavity. One patient (3%) achieved complete response (CR) and 18 patients had partial responses (PR) to IC. CCRT 
enhanced the response rate, resulting in a total of 3 CR (10%) and 16 PR (53%) to treatment. The median time to 
progression was 11.5 months. The median overall survival was 27 months. The most severe hematologic toxicity 
occurred during IC was grade3-4 neutropenia (40%). Grade 3-4 mucositis occurred in 68% of patients during CCRT.  
Conclusion: This novel combined-modality treatment program, is toxic but feasible, and can be administered for 
selected patients with advanced and unresectable head and neck cancer. © 2010 Biomedical Imaging and Intervention 
Journal. All rights reserved. 
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INTRODUCTION 
It is generally accepted that the treatment of locally 
advanced squamous cell carcinoma of head and neck 
cancer (SCCHN) should involve a combined modality 
approach. Surgery and/or radiotherapy is the main 
definitive of therapy in patients with locally advanced 
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SCCHN. Induction chemotherapy followed by 
concurrent chemoradiotherapy is a promising treatment 
in this group of patients. 
Up to 30-50% of chemonaive locally advanced 
SCCHN patients treated with cisplatin-5FU (PF) have 
been reported to achieve a complete response rate at 
primary sites, with an overall response rate of 
70-88%.[1-3] The main toxicities associated with 
PF-induction therapy are hematological, digestive and 
mucositis with the majority of events being grade 1 or 
2.[2,4] Despite the high overall response rates, the low 
CR rates at primary sites and the high rate of 
locoregional recurrence in patients with extensive lymph 
node disease have been disappointing.[2,4,5] 
The results of many phase III trials [6-9] show that 
adding taxane (T) to the standard cisplatin and 5-FU 
regimen improved the overall survival rate and led to 
better organ preservation over a PF regimen. A phase II 
study combining paclitaxel, ifosfamide and cisplatin (TIP) 
to treat recurrent and metastatic SCCHN produced a high 
overall response rates (54%) including prolonged 
duration of CR and encouraging one-and two-year 
median survival rates.[10] 
As an induction chemotherapy for locally advanced 
head and neck cancer, a phase II study combining 
paclitaxel, ifosfamide and carboplatin resulted in a high 
overall response rate of approximately 80%. [11] Based 
on the demonstrated activity of this triplet regimen in 
SCCHN and their non-overlapping toxicity profiles, the 
combination was promising. This single-center, open-
label, non-randomized phase II study evaluated tumor 
response of induction chemotherapy with paclitaxel, 
ifosfamide, and cisplatin followed by concurrent 
chemoradiotherapy with cisplatin for locally advanced 
head and neck cancer, as well as the therapeutic efficacy 
on overall survival and time to disease progression. 
PATIENTS AND METHODS 
Patient characteristics 
Patients were eligible if they had histologically 
confirmed SCCHN, at least one bidimensionally 
measurable lesion, aged 18-70 years, stage III or IV 
(AJCC staging 2002) disease without distant metastases, 
an ECOG performance status of 0 to1, and adequate 
bone marrow/hepatic/and renal function. Patients with 
primary sites in the oral cavity, oropharynx, larynx, 
hypopharynx, nasal cavity and paranasal sinus were 
eligible. Patients were excluded from the study if they 
had primary sites of the nasopharynx or salivary glands. 
Patients who had been treated for a previous SCCHN, 
had severe intercurrent medical illness, or known 
peripheral neuropathy were also excluded from the study. 
Patients were required to give written informed consent 
before inclusion in the study. The institutional review 
board of the Faculty of Medicine, Chiang Mai University, 
approved the study. The study was conducted in 
accordance with the principles of the Declaration of 
Helsinki. 
Treatment 
Induction chemotherapy (IC) 
Eligible patients underwent 2 cycles of IC 
(paclitaxel 175 mg/m
2 in a three-hour infusion on day 1, 
ifosfamide 1000 mg/m
2 in a two-hour infusion on day 
1-3 with uromitexan 200 mg/m
2 IV in 15 minutes at the 
time of administration of ifosfamide, and then at 4 and 
8 hours, and cisplatin 60 mg/m
2 as a 90-minute infusion 
on day 1). Head and neck examination and repeated 
CT  scan of the head and neck were performed to 
evaluate the initial response after completion of 2 cycles 
of IC regimen. If the patients achieved a partial response 
(PR), or complete response (CR), they received 2 more 
cycles of the same IC. Patients who achieved stable 
disease (SD) or progressed from the initial 2 cycles of 
chemotherapy did not receive the same induction 
chemotherapy regimen and were treated according to the 
discretion of the physicians. 
Concurrent chemoradiotherapy (CCRT) 
Patients who achieved PR or CR after 2 cycles of IC 
and received additional 2 cycles of IC underwent 
concurrent with cisplatin 80 mg/m
2 every 3 weeks for 
3 cycles. Radiotherapy was administered once daily as 
200 cGy per fraction to a total dose of 6600-7000 cGy. 
Treatment protocol is shown in Figure 1. During 
treatment, patients were evaluated for toxicity according 
to the NCI/CTC version 2.0. 
Dose Modification 
Dose modifications during IC were based on 
complete blood count (CBC). For ANC <1,500/mm
3 or 
platelet <100,000/mm
3, chemotherapy was delayed for 
1  week until recovery and administered with the same 
dose. If ANC <1,000/mm
3 or platelet <75,000/mm
3, 
chemotherapy was delayed for 1 week until recovery and 
administered with a reduced dose of 50%. During CCRT; 
for ANC< 1,500 or platelet < 100,000/mm
3 or in field 
toxicity of grade 3, radiotherapy and chemotherapy were 
withheld until recovery from radiation-induced toxicity 
of grade <2 and normal CBC. 
Statistical Analysis 
Response evaluation was performed after 2 cycles of 
IC, and 3 months after completion of CCRT in all treated 
patients. Intent-to-treat analysis was performed. Survival 
was measured from the date of study entry until date of 
last follow-up or death. Time to progression was 
measured as time from the first day of treatment until 
disease progression. 
RESULTS 
Between June 2003 and June 2005, 30 patients with 
locally advanced SCCHN were accrued to the study. The 
median age of patients was 53 years, range 30-70 years. 
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Figure 1 Protocol  Schema 
 
Induction chemotherapy (IC): TIP regimen 
Paclitaxel 175 mg/ m
2   day 1 
Ifosfamide 1 gm/m
2   day 1-3 
Cisplatin 60 mg/ m
2   day 1 
x2 cycles (n=30) 
PR/CR (n=19) 
CR =   1 
PR =  18 
SD/PD (n=11) 
Additional IC: TIP x2 cycles 
: SD = palliative RT (n=3) 
: PD = palliative RT (n=3) 
Rx according to the 
discretion of the physician 
: SD = radical RT (n=5) 
Concurrent chemoradiotherapy (CCRT) 
Cisplatin 80 mg/m
2 q 3 weeks x3 cycles 
Radiotherapy 6600-7000 cGy 
(n=19) 
Completion of CCRT (n=19) 
Clinical CR (n=3) 
Clinical PR (n=16) 
Intent-to-treat Analysis for survival (n=30) 
No evidence of disease (n=3) 
Living with disease (n=13) 
Died from disease (n=14) 
Assessment (n=30) 
(CR= complete response, PR = partial response,  
  SD = stable disease, PD = progression of disease) 
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All patients had stage III or IV disease and 90% had 
stage IV disease. The baseline patient characteristics are 
summarized in Table 1. 
Response to induction chemotherapy 
After 2 cycles of IC, all patients were evaluated for 
response. One of 30 patients had a complete response, 
18  patients had partial response, 8 patients had stable 
disease, and 3 patients had progressive disease. The 
overall response rate after 2 cycles of IC was 63% 
(Table  2). Three patients with progressive disease 
associated with poor performance status were treated 
with palliative radiotherapy. Among 8 patients who had 
stable disease, 5 of them received radical radiotherapy 
and the other 3 patients received palliative radiotherapy 
due to poor performance status. Only 19 patients who 
had CR and PR continued their third and forth cycles of 
IC. The overall response rate at 4 cycles of IC in 19 cases 
was 100% (Table 2). 
Response after concurrent chemoradiotherapy 
Nineteen patients who completed their 4 cycles of 
induction chemotherapy were treated with concurrent 
cisplatin and radiotherapy. All of them completed the 
whole treatment planned. There were 2 additional 
patients who achieved a complete clinical response at the 
tumor. Sixteen patients had residual disease after 
chemoradiotherapy (Table 2). Ten patients did not have 
salvage surgery because they either had developed 
distant metastases (2 patients), refused surgery 
(3  patients), and still had unresectable disease 
(5 patients). Six patients had salvage surgery following 
concurrent chemoradiotherapy, five of them eventually 
developed a neck recurrence, another patient had 
progression of disease at the primary site. 
Toxicity of induction chemotherapy  
Toxicity was assessed in all 30 patients (Table 3). 
Myelosuppression was frequent, with grade 3-4 
neutropenia in 40% of patients. No treatment - related 
deaths occurred in this study. Neuropathy of any grade 
was found in 50% of patients. Neurosensory deficits on 
both hands were common. 
Toxicity of concurrent chemotherapy 
Toxicity was assessed in 19 patients who received 
concurrent chemoradiotherapy (Table 3). Seventeen 
percent of patient had grade 3-4 neutropenia. Severe 
grade 3 mucositis occurred in 68% of patients. However, 
prolongation of the RT schedule to 8 weeks was 
observed in only 2 of 19 patients. 
Time to progression of disease and survival 
With a median follow-up of 20.6 months and a 
range of 6.1 to 68 months as of March 2009, we 
performed the intent-to-treat analysis in all 30 patients 
(Figure 1). At the time of analysis, 3 patients (10%) were 
alive and had no evidence of disease with a minimum 
follow-up of 39.5 months. Thirteen patients (43%) were 
alive with disease. Fourteen patients (47%) died from 
disease. The median time to progression was 
11.5  months (Figure 2) and median survival time was 
27 months (Figure 3). 
DISCUSSION 
Nineteen of 30 patients with locally advanced head 
and neck cancer who achieved CR or PR after induction 
chemotherapy of paclitaxel/ifosfamide/cisplatin followed 
by concurrent radiotherapy with cisplatin, demonstrated 
overall response rate of 90% and the median survival 
time of 27 months. Volkes et al. study, focusing on 
induction chemotherapy with weekly carboplatin and 
paclitaxel before intensive concomitant 
chemoradiotherapy with hydroxyurea [12] reported the 
overall best response of 87%. Our phase II study 
included patients with stage III/IV disease with 90% of 
them having stage IV disease which is comparable with 
their study (96% stage IV). Not surprisingly, our results 
had a lower survival outcome than other induction 
chemotherapy studies. This is because, in this study, 
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Figure 2  Time to progression. 
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Figure 3  Overall survival. 
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Table 1 Patient  Characteristics 
Characteristics No  (%) 
No. of patients  30 
Age, median (range)  53 (30-70) 
Sex  
Male 21  (70) 
Female    9 (30) 
ECOG performance status   
0 18  (60) 
1 12  (40) 
Primary site   
Oral cavity    6 (20) 
Oropharynx    8 (27) 
Larynx    1 (3) 
Hypopharynx    3 (10) 
Paranasal sinus + nasal cavity  12 (40) 
Stage  
III    3 (10) 
IV 27  (90) 
 
 
 
 
Table 2 Response  Rate 
Response  After IC 2 cycles (%)  
(n=30) 
After IC 4 cycles (%)  
(n= 19) 
After CCRT (%)  
(n=19) 
CR    1 (3)    1 (5)    3 (16) 
PR  18 (60)  18 (95)  14 (74) 
SD    8 (27)    -    2 (10) 
PD    3 (10)    -    - 
 
 
 
 
Table 3  Toxicities (NCI/CTC v.2.0) 
Grade 0  1  2  3  4 
Toxicities of IC (% of patients) (n= 30)           
Anemia 33  60  3  4  - 
Neutropenia -  27  33  37  3 
Thrombocytopenia 63  30  -  6  1 
Neuropathy 50  50  -  -  - 
Fatigue -  67  33  -  - 
Nausea -  33  67  -  - 
Alopecia -  -  100  -  - 
Toxicities of CCRT (% of patients) (n=19)           
Anemia 11  63  26  -  - 
Neutropenia 16  53  14  16  1 
Thrombocytopenia 53  42  -  5  - 
Fatigue -  100  -  -  - 
Nausea  - 79 21 -  - 
Vomiting  - 74 26 -  - 
Radiation induced mucositis  -  5  27  68  - 
Radiation induced pharyngitis  -  16  84  -  - 
Radiation induced dermatitis  -  74  26  -  - 
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11  patients (37%) who had stable disease and 
progression of disease did not receive further 2 cycles of 
induction chemotherapy, none of them received 
concurrent chemoradiotherapy, and six of them (55%) 
received only additional palliative radiotherapy due to 
their poor performance status. 
Compared to the previous study of Shin et al [11], 
which had almost the same treatment scheme as ours, 
except for the regimen of induction chemotherapy, we 
replaced cisplatin instead of carboplatin, and show a 
comparable response rate but a much lower survival rate. 
Unlike our study, Shin et al. found that only 10 of 44 
(23%) of patients had stable disease and progressive 
disease after 2 cycles of induction chemotherapy. 
Patients then received further treatment with only local 
therapy, and 4 of 10 (40%) still had no evidence of 
disease at the time of their analysis. One factor that 
contributed to the poorer outcome than prior induction 
studies was the tumor subsite. In our study, the primary 
site of the paranasal sinus and nasal cavity were much 
more prevalent than in the other studies (40% versus 
0-1%). We knew that the nature of this disease was 
disappointing, especially in advanced stages, and all 40% 
of our patients with paranasal sinus cancer were in stage 
IV of the disease. 
There were no therapy-related deaths. 
Administration of induction TIP regimen was associated 
with grade 4 neutropenia and thrombocytopenia in only 
3% and 1%, respectively. The administration of 
subsequent concurrent chemoradiotherapy was not 
compromised. We found only a 1% instance of grade 4 
neutropenia during CCRT. Radiation induced mucositis 
and pharyngitis were common side effects but no one 
delayed the schedule of radiotherapy. 
In summary, we observed a 63% overall response 
rate of two cycles of induction chemotherapy and as high 
as 90% after CCRT, and the 27-month median survival 
with TIP regimen, establishing it as an effective regimen 
with high but manageable toxicities for locally advanced 
head and neck cancer. However, the inferior survival 
outcome to prior studies emphasizes the importance of 
patient selection according to performance status and 
primary tumor site to achieve a favorable outcome. 
Aggressive nutritional support should be considered in 
patients receiving this regimen, to improve acute 
palliation and to maximize the delivery of combined-
modality therapy. Patients with poor performance status 
or primary tumors involving the paranasal sinus/nasal 
cavity may not be good candidates.  
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